Penelope Korkolopoulou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11797432/publications.pdf

Version: 2024-02-01

108 papers 4,371 citations

76326 40 h-index 62 g-index

108 all docs 108 docs citations

108 times ranked 7115 citing authors

#	Article	IF	Citations
1	Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium. Brain Pathology, 2008, 18, 484-496.	4.1	361
2	Discerning the Ancestry of European Americans in Genetic Association Studies. PLoS Genetics, 2008, 4, e236.	3.5	281
3	Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 635-652.	7.7	249
4	Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochemistry and Cell Biology, 2007, 127, 581-589.	1.7	151
5	Assessment of \hat{l}^2 -amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 309-320.	7.7	143
6	Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2006, 65, 740-757.	1.7	95
7	Inter-laboratory comparison of neuropathological assessments of \hat{l}^2 -amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 533-546.	7.7	86
8	Accumulation of dietary glycotoxins in the reproductive system of normal female rats. Journal of Molecular Medicine, 2007, 85, 1413-1420.	3.9	84
9	Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer. Modern Pathology, 2007, 20, 159-166.	5.5	78
10	The Role of p53, MDM2 and c-erb B-2 Oncoproteins, Epidermal Growth Factor Receptor and Proliferation Markers in the Prognosis of Urinary Bladder Cancer. Pathology Research and Practice, 1997, 193, 767-775.	2.3	77
11	Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy. Oncologist, 2013, 18, 190-197.	3.7	77
12	Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?. Blood, 2014, 123, 1199-1206.	1.4	76
13	Assessment of \hat{l}_{\pm} -Synuclein Pathology: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2008, 67, 125-143.	1.7	73
14	Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1/2–NF-κB and JNK–AP-1 signaling pathways. Cellular and Molecular Life Sciences, 2016, 73, 1685-1698.	5.4	70
15	c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology, 2004, 63, 1198-1204.	1.0	69
16	Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Molecular and Cellular Biochemistry, 2007, 304, 343-351.	3.1	65
17	Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators. Human Pathology, 2005, 36, 899-907.	2.0	63
18	Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine, 2007, 39, 99-105.	3.2	62

#	Article	IF	CITATIONS
19	Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood, 2005, 105, 1875-1880.	1.4	61
20	Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue. Journal of Cellular and Molecular Medicine, 2010, 14, 2460-2469.	3.6	57
21	The need to unify neuropathological assessments of vascular alterations in the ageing brain. Experimental Gerontology, 2012, 47, 825-833.	2.8	57
22	Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis. BMC Cancer, 2016, 16, 174.	2.6	55
23	Differential Expression of bcl-2 Family Proteins in Bladder Carcinomas. European Urology, 2002, 41, 274-283.	1.9	52
24	Clinical significance of nuclear factor (NF)-lºB levels in urothelial carcinoma of the urinary bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 295-304.	2.8	52
25	A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3â€kinase/vâ€akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU International, 2012, 110, E1237-48.	2.5	52
26	Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert's personal archive. Histopathology, 2011, 59, 679-691.	2.9	51
27	Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncology Reports, 2012, 27, 1630-8.	2.6	50
28	Expression of nuclear factor-l̂ºB in human astrocytomas: relation to pll̂ºBa, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Human Pathology, 2008, 39, 1143-1152.	2.0	49
29	High Incidence of MGMT and RAR \hat{l}^2 Promoter Methylation in Primary Glioblastomas: Association with Histopathological Characteristics, Inflammatory Mediators and Clinical Outcome. Molecular Medicine, 2010, 16, 1-9.	4.4	48
30	The Combined Evaluation of p27Kip1 and Ki-67 Expression Provides Independent Information on Overall Survival of Ovarian Carcinoma Patients. Gynecologic Oncology, 2002, 85, 404-414.	1.4	47
31	Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. European Journal of Haematology, 2006, 77, 300-303.	2,2	47
32	Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Human Pathology, 2007, 38, 629-638.	2.0	47
33	Analysis of interleukin (IL)-8 expression in human astrocytomas: Associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Human Immunology, 2009, 70, 391-397.	2.4	47
34	Revising the historical collection of epithelioid cell-rich lymphomas of the Kiel Lymph Node Registry: what is Lennert's lymphoma nowadays?. Histopathology, 2011, 59, 1173-1182.	2.9	47
35	Phosphorylated 4Eâ€binding protein 1 (pâ€4Eâ€BP1): a novel prognostic marker in human astrocytomas. Histopathology, 2012, 61, 293-305.	2.9	46
36	Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 473-485.	2.8	46

#	Article	IF	Citations
37	Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: Correlation with IL-6, VEGF and microvessel morphometry. Cytokine, 2011, 55, 387-395.	3.2	45
38	Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood, 2018, 132, 666-670.	1.4	44
39	Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival. Acta Neuropathologica, 1998, 95, 617-624.	7.7	43
40	Morphometric microvascular characteristics predict prognosis in superficial and invasive bladder cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 603-611.	2.8	43
41	Reduced Ovarian Glyoxalase-I Activity by Dietary Glycotoxins and Androgen Excess: A Causative Link to Polycystic Ovarian Syndrome. Molecular Medicine, 2012, 18, 1183-1189.	4.4	43
42	Prognostic Implications of Aberrations in p16/pRb Pathway in Urothelial Bladder Carcinomas: A Multivariate Analysis Including p53 Expression and Proliferation Markers. European Urology, 2001, 39, 167-177.	1.9	41
43	A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncology Reports, 2013, 30, 623-636.	2.6	41
44	Polycystinâ€1 and polycystinâ€2 are involved in the acquisition of aggressive phenotypes in colorectal cancer. International Journal of Cancer, 2015, 136, 1515-1527.	5.1	41
45	Expression of nuclear factor κB in human gastric carcinoma: relationship with IκBa and prognostic significance. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 519-527.	2.8	37
46	Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leukemia and Lymphoma, 2011, 52, 387-393.	1.3	35
47	Highâ€frequency <i>p16</i> <scp>^{<i>INK</i>}</scp> ^{<i>4A</i>} promoter methylation is associated with histone methyltransferase <scp>SETDB</scp> 1 expression in sporadic cutaneous melanoma. Experimental Dermatology, 2014, 23, 332-338.	2.9	33
48	Non-gastric extra-nodal marginal zone lymphomas–a single centre experience on 76 patients. Leukemia and Lymphoma, 2008, 49, 2308-2315.	1.3	32
49	Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Molecular and Cellular Biochemistry, 2007, 295, 75-83.	3.1	31
50	Prognostic significance of replication protein A (RPA) expression levels in bladder urothelial carcinoma. BJU International, 2011, 108, E59-65.	2.5	31
51	ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. World Journal of Surgical Oncology, 2012, 10, 47.	1.9	31
52	Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. PLoS ONE, 2015, 10, e0133859.	2.5	31
53	Isolated central nervous system relapses in primary mediastinal large Bâ€cell lymphoma after CHOPâ€like chemotherapy with or without Rituximab. Hematological Oncology, 2013, 31, 10-17.	1.7	30
54	WAF1/p21 Protein Expression Is an Independent Prognostic Indicator in Superficial and Invasive Bladder Cancer. Applied Immunohistochemistry & Molecular Morphology, 2000, 8, 285-292.	2.0	29

#	Article	IF	CITATIONS
55	Reduced retinoblastoma gene protein to ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients. Gynecologic Oncology, 2003, 88, 369-378.	1.4	26
56	Comparative Assessment of Proliferating Cell Nuclear Antigen Immunostaining and of Nucleolar Organizer Region Staining in Transitional Cell Carcinomas of the Urinary Bladder. European Urology, 1992, 22, 235-240.	1.9	25
57	Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. Journal of Neural Transmission, 2015, 122, 957-972.	2.8	25
58	Topoisomerase IIα Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma. Clinical Cancer Research, 2008, 14, 1759-1766.	7.0	24
59	Immunohistochemical expression and prognostic significance of CCND3, MCM2 and MCM7 in Hodgkin lymhoma. Anticancer Research, 2011, 31, 3585-94.	1.1	24
60	Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations. Pathology, 2009, 41, 327-334.	0.6	23
61	D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1563-1571.	2.5	22
62	Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphoma. Leukemia and Lymphoma, 2012, 53, 1481-1487.	1.3	21
63	Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 207-217.	2.8	21
64	A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides. Journal of the American Academy of Dermatology, 2013, 69, 375-384.	1.2	20
65	Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients. World Journal of Urology, 2017, 35, 411-419.	2.2	20
66	Apoptosis in bladder carcinomas detected with monoclonal antibody to single-stranded DNA: relation to cell cycle regulators and survival. Urology, 2000, 56, 516-520.	1.0	19
67	The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma. BMC Cancer, 2014, 14, 149.	2.6	18
68	Immunohistochemical and molecular analysis of PI3K/ <scp>AKT</scp> /m <scp>TOR</scp> pathway in esophageal carcinoma. Apmis, 2015, 123, 639-647.	2.0	18
69	Polycystin-1 induces activation of the PI3K/AKT/mTOR pathway and promotes angiogenesis in renal cell carcinoma. Cancer Letters, 2020, 489, 135-143.	7.2	18
70	Apoptosis detected with monoclonal antibody to single-stranded DNA is a predictor of recurrence in intracranial meningiomas. Journal of Neuro-Oncology, 2001, 55, 1-9.	2.9	17
71	A morphometric study of bone marrow angiogenesis in hairy cell leukaemia with clinicopathological correlations. British Journal of Haematology, 2003, 122, 900-910. Immunohistochemical Analysis of IL-6, IL-8/CXCR2 Axis, <mml:math <="" td="" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td>2.5</td><td>17</td></mml:math>	2.5	17

id="M1"><mml:msup><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mtext>Tyr</mml:mtext></mml:maid SOCS-3 in Lymph Nodes from Patients with Chronic Lymphocytic Leukemia: Correlation between Microvascular Characteristics and Prognostic Significance. BioMed Research International, 2014, 2014, 1-13.

#	Article	IF	Citations
73	New Insights into Monoclonal B-Cell Lymphocytosis. BioMed Research International, 2014, 2014, 1-11.	1.9	17
74	Clinical Aspects of Malt Lymphomas. Current Hematologic Malignancy Reports, 2014, 9, 262-272.	2.3	17
75	Replication Protein A in Nonearly Ovarian Adenocarcinomas. International Journal of Gynecological Pathology, 2012, 31, 319-327.	1.4	16
76	Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 749-759.	2.8	15
77	Expression of Interleukin-8 Receptor CXCR2 and Suppressor of Cytokine Signaling-3 in Astrocytic Tumors. Molecular Medicine, 2012, 18, 379-388.	4.4	15
78	Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review. Advances in Anatomic Pathology, 2016, 23, 202-243.	4.3	15
79	Earlyâ€Stage Gastric MALT Lymphoma: Is It a Truly Localized Disease?. Oncologist, 2009, 14, 148-154.	3.7	13
80	Replication protein A: a reliable biologic marker of prognostic and therapeutic value in human astrocytic tumors. Human Pathology, 2011, 42, 1545-1553.	2.0	13
81	Dietary glycotoxins induce RAGE and VEGF up-regulation in the retina of normal rats. Experimental Eye Research, 2015, 137, 1-10.	2.6	13
82	Polycystin-1 downregulation induces ERK-dependent mTOR pathway activation in a cellular model of psoriasis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3468-3476.	3.8	13
83	Expression and Prognostic Significance of Cyclin D3 in Ovarian Adenocarcinomas. International Journal of Gynecological Pathology, 2007, 26, 410-417.	1.4	11
84	Detection of L265P <i>MYDâ€88</i> mutation in a series of clonal Bâ€cell lymphocytosis of marginal zone origin (CBLâ€MZ). Hematological Oncology, 2017, 35, 542-547.	1.7	10
85	TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis. Pathology, 2013, 45, 138-144.	0.6	9
86	Impact of Androgen and Dietary Advanced Glycation End Products on Female Rat Liver. Cellular Physiology and Biochemistry, 2015, 37, 1134-1146.	1.6	9
87	Analysis of PRNP Gene Codon 129 Polymorphism in the Greek Population. European Journal of Epidemiology, 2006, 21, 211-215.	5.7	8
88	Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2014, 55, 571-582.	1.3	7
89	Impact of diet-induced obesity in male mouse reproductive system: The role of advanced glycation end product–receptor for advanced glycation end product axis. Experimental Biology and Medicine, 2014, 239, 937-947.	2.4	7
90	Multifocal Bilateral Breast Cancer and Breast Follicular Lymphoma: A Simple Coincidence?. Journal of Breast Cancer, 2015, 18, 296.	1.9	7

#	Article	IF	Citations
91	Polycystin†regulates cell proliferation and migration through AKT/mTORC2 pathway in a human craniosynostosis cell model. Journal of Cellular and Molecular Medicine, 2022, 26, 2428-2437.	3.6	7
92	Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome. Scientific Reports, 2016, 6, 21252.	3.3	6
93	No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab. Leukemia and Lymphoma, 2016, 57, 2705-2708.	1.3	5
94	Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations. Pathology Research and Practice, 2018, 214, 826-834.	2.3	5
95	Laying the groundwork for the Biobank of Rare Malignant Neoplasms at the service of the Hellenic Network of Precision Medicine on Cancer. International Journal of Oncology, 2022, 60, .	3.3	5
96	Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-Î ³ expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications. Leukemia and Lymphoma, 2017, 58, 2227-2239.	1.3	4
97	A Unique Case of Primary Extranodal Marginal Zone Lymphoma of the Anal Canal. Acta Haematologica, 2019, 142, 87-91.	1.4	4
98	Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) Blood, 2006, 108, 2745-2745.	1.4	4
99	TGF-Î ² RII, BAX, IGFIIR, caspase-5, hMSH3 and hMSH6 alterations are not associated with microsatellite instability or p53 mutations in invasive urothelial carcinoma of the urinary bladder. Pathology, 2007, 39, 425-432.	0.6	3
100	The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas. Neurology Research International, 2012, 2012, 1-13.	1.3	3
101	Methylation analysis of APC, AXIN2, DACT1, RASSF1A and MGMT gene promoters in non-small cell lung cancer. Pathology Research and Practice, 2022, 234, 153899.	2.3	2
102	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with concurrent high grade component at diagnosis: clinico-pathologic features and treatment strategy. Leukemia and Lymphoma, 2015, 56, 3230-3232.	1.3	1
103	WAF1/p21 Protein Expression Is an Independent Prognostic Indicator in Superficial and Invasive Bladder Cancer. Applied Immunohistochemistry and Molecular Morphology, 2000, 8, 285-292.	1.2	О
104	Additive effects of dietary glycotoxins and androgen excess on the kidney of a female rat model. Alexandria Journal of Medicine, 2016, 52, 159-168.	0.6	0
105	Retrospective Analysis of 41 Consecutive Patients with Non Gastrointestinal (GI) Extranodal Marginal Zone B-Cell Lymphoma (EMZL): Correlation of Clinical Characteristics and Outcome with Disease Localization Blood, 2005, 106, 4785-4785.	1.4	O
106	Z-Guggulsterone Downregulates Survivin and Induces Cell Death in Large B Cell Lymphoma Cells In Vitro Blood, 2006, 108, 4752-4752.	1.4	0
107	B-Chronic Lymphoproliferative Disorders (BCLD) Presenting with Splenomegaly: Differential Diagnosis and Outcome Blood, 2006, 108, 4655-4655.	1.4	O
108	Symptomatic ovarian involvement as the initial presentation of primary mediastinal large b-cell lymphoma. Gynecologic Oncology Reports, 2022, 41, 100988.	0.6	0